Mdm2 gene amplification in gastric cancer correlation with expression of mdm2 protein and p53 alterations

Citation
T. Gunther et al., Mdm2 gene amplification in gastric cancer correlation with expression of mdm2 protein and p53 alterations, MOD PATHOL, 13(6), 2000, pp. 621-626
Citations number
33
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Medical Research Diagnosis & Treatment
Journal title
MODERN PATHOLOGY
ISSN journal
08933952 → ACNP
Volume
13
Issue
6
Year of publication
2000
Pages
621 - 626
Database
ISI
SICI code
0893-3952(200006)13:6<621:MGAIGC>2.0.ZU;2-G
Abstract
Mdm2, localized on chromosome 12, is considered a negative regulator of p53 function and seems to play a role in the pathogenesis of a variety of tumo rs, The mdm2 amplification in advanced-stage gastric carcinoma has not yet been investigated, Mdm2 amplification was determined in 43 gastric carcinomas, and the genetic results were correlated with mdm2 protein expression, p53 alterations, and clinicopathologic data. The tumors were classified according to Lauren: 20 intestinal-type tumors, 19 tumors of diffuse growth inclusive of a primary small cell carcinoma, and 4 carcinomas with mixed differentiation. Staging was based on the pTNM classification system. Mdm2 and p53 were demonstrate d by immunohistology on formalin-fixed and paraffin-embedded tumor tissue. The mdm2 oncogene was amplified by nonradioactive hybridization of tumor DN A with an mdm2 cDNA probe. The Southern blots were evaluated densitometrica lly. For p53 mutation screening, we analyzed the highly conservative region s of the p53 gene (exons 4 to 8) with the use of the polymerase chain react ion-single-strand conformation polymorphism technique. Polymerase chain rea ction products with band shifting were directly sequenced. Mdm2 amplification was demonstrated in 18 tumors (41.8%). The mdm2 gene was amplified more frequently in carcinomas with a diffuse growth pattern, Gas tric carcinomas of the intestinal type, however, showed a higher frequency of p53 alterations. There was no statistical significance of the molecular genetic and immunohistologic results of the mdm2/p53 status to staging as w ell as to age and sex of the patients. The mdm2/p53 pathway is a part of the carcinogenesis of gastric carcinoma O nly approximately 20% of gastric carcinomas failed to show mdm2 and/or p53 alterations. The upregulation of the mdm2 oncogene and the accompanying ina ctivation of the tumor suppressor gene 53 seem to play a role above all in carcinomas of the diffuse type.